Recent Updates
Recently added Catalysts
QTRX Positive Sentiment Score: 70/100

Quanterix Releases Financial Results for the First Quarter of 2024 BILLERICA, Mass. - May 7 , 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection

Key Takeaway: Quanterix Corporation announced its financial results for the first quarter of 2024, revealing a focus on innovation in biomarker detection. The company expects total revenue between $139 to $144 million for the year, while reporting a net loss of $10,072. The CEO highlighted the launch of new assays aimed at improving the measurement of Tau and enhancing the early detection of neuro-pathologies. Despite increasing operating expenses and a higher net loss compared to the previous year, Quanterix maintains a strong outlook for its research-only business.

Market Sentiment Analysis

POSITIVE FACTORS

  • Quanterix is entering a new phase of innovation and product delivery.
  • New assays could redefine Tau measurement, enhancing research capabilities.
  • The company continues to expect strong revenue guidance for 2024.
  • Their focus on neuro-pathologies positions them well for future growth.

CONCERNS & RISKS

  • Net loss increased to $10,072, which is higher compared to the previous year.
  • Total operating expenses rose significantly, impacting net income.

Full Press Release Details

Quanterix Releases Financial Results for the First Quarter of 2024
BILLERICA, Mass. - May 7, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024.
"Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase," said Masoud Toloue, Chief Executive Officer of Quanterix. "We've announced the first of several new assays that could re-define the way Tau is measured, from the brain versus peripheral sources. We will continue to lead in bringing novel biomarker detection solutions to market for the research community; developing tests to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson's, and Alzheimer's disease."
First Quarter Financial Highlights
Operational and Business Highlights
2024 Full Year Business Outlook
The Company's 2024 financial guidance is unchanged. Management continues to expect full-year 2024 revenue in the range of $139 to $144 million. This guide is for the Company's research-only business, and does not include revenues from Diagnostics testing, which to date have not been material. GAAP gross margin percentage is expected to be in the range of 57-61%, and non-GAAP gross margin percentage is expected to be in the range of 51-55%. Finally, the Company continues to anticipate 2024 cash usage in the range of $25 to $30 million.
For additional information on the non-GAAP financial measures included in this press release, please see "Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures" below.
In conjunction with this announcement, the Company will host a conference call on May 08, 2024 at 8:30 a.m. E.T. Click here to pre-register for the conference call and obtain your dial-in number and passcode.
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company's website for one year.
Financial Highlights
Quanterix Corporation
Consolidated Statements of Operations
(Unaudited and in thousands, except per share data)
Three Months Ended March 31,
2024 2023
Revenues:
Product revenue $ 19,670 $ 19,287
Service and other revenue 11,967 8,579
Collaboration and license revenue 155 368
Grant revenue 274 222
Total revenues 32,066 28,456
Costs of goods sold and services:
Cost of product revenue 7,145 7,033
Cost of service and other revenue 5,295 4,497
Total costs of goods sold and services 12,440 11,530
Gross profit 19,626 16,926
Operating expenses:
Research and development 6,675 4,720
Selling, general, and administrative 25,993 20,850
Other lease costs 924 776
Total operating expenses 33,592 26,346
Loss from operations (13,966) (9,420)
Interest income, net 3,948 3,449
Other income, net 206 8
Loss before income taxes (9,812) (5,963)
Income tax expense (260) (140)
Net loss $ (10,072) $ (6,103)
Net loss per common share, basic and diluted $ (0.26) $ (0.16)
Weighted-average common shares outstanding, basic and diluted 38,126 37,327
Quanterix Corporation
Consolidated Balance Sheets
(Unaudited and in thousands)
March 31, 2024 December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents $ 45,281 $ 174,422
Marketable securities 256,640 146,902
Accounts receivable 29,276 25,414
Inventory 26,015 22,365
Prepaid expenses and other current assets 9,551 9,291
Total current assets 366,763 378,394
Restricted cash 2,605 2,604
Property and equipment, net 17,492 17,926
Intangible assets, net 5,339 6,034
Operating lease right-of-use assets 17,748 18,251
Other non-current assets 1,802 1,802
Total assets $ 411,749 $ 425,011
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 3,914 $ 5,048
Accrued compensation and benefits 6,706 13,659
Accrued expenses and other current liabilities 7,021 6,041
Deferred revenue 10,234 9,468
Operating lease liabilities 4,366 4,241
Total current liabilities 32,241 38,457
Deferred revenue, net of current portion 933 1,227
Operating lease liabilities, net of current portion 36,084 37,223
Other non-current liabilities 1,053 1,177
Total liabilities 70,311 78,084
Total stockholders' equity 341,438 346,927
Total liabilities and stockholders' equity $ 411,749 $ 425,011
Quanterix Corporation
Consolidated Statements of Cash Flows
(Unaudited and in thousands)
Three Months Ended March 31,
2024 2023
Cash flows from operating activities:
Net loss $ (10,072) $ (6,103)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense 1,523 1,439
Credit losses on accounts receivable 176 178
Accretion of marketable securities (1,657) -
Operating lease right-of-use asset amortization 478 334
Stock-based compensation expense 5,265 3,902
Other operating activity 55 270
Changes in assets and liabilities:
Accounts receivable (4,233) (3,741)
Inventory (3,670) (89)
Prepaid expenses and other current assets (254) (422)
Other non-current assets (21) (33)
Accounts payable (1,122) (1,271)
Accrued compensation and benefits, accrued expenses, and other current liabilities (6,126) (5,983)
Deferred revenue 472 2,041
Operating lease liabilities (988) 179
Other non-current liabilities 10 (203)
Net cash used in operating activities (20,164) (9,502)
Cash flows from investing activities:
Purchases of marketable securities (137,889) -
Proceeds from maturities of marketable securities 29,200 -
Purchases of property and equipment (506) (136)
Net cash used in investing activities (109,195) (136)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans 2,037 564
Payments for employee taxes withheld on stock-based compensation awards (1,438) (13)
Net cash provided by financing activities 599 551
Net decrease in cash, cash equivalents, and restricted cash (128,760) (9,087)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (380) 24
Cash, cash equivalents, and restricted cash at beginning of period 177,026 341,337
Cash, cash equivalents, and restricted cash at end of period $ 47,886 $ 332,274
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a U.S. GAAP basis, we present non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, and non-GAAP loss from operations, which are calculated by including shipping and handling costs for product sales within cost of goods sold instead of within selling, general, and administrative expenses. Management uses these non-GAAP measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. Management believes that presentation of these non-GAAP measures provides useful information to investors in assessing our operating performance within our industry and in order to allow comparability to the presentation of other companies in our industry where shipping and handling costs are included in cost of goods sold for products. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with U.S. GAAP. Set forth below is a reconciliation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, and non-GAAP loss from operations to their most directly comparable GAAP financial measures.
Reconciliation of GAAP to Non-GAAP Financial Measures
Quanterix Corporation
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(Unaudited and in thousands, except percentages)
Three Months Ended March 31,
2024 2023
GAAP gross profit $ 19,626 $ 16,926
Shipping and handling costs (1) (2,142) (1,829)
Non-GAAP gross profit $ 17,484 $ 15,097
GAAP revenue $ 32,066 $ 28,456
GAAP gross margin (gross profit as % of revenue) 61.2% 59.5%
Non-GAAP gross margin (non-GAAP gross profit as % of revenue) 54.5% 53.1%
GAAP total operating expenses $ 33,592 $ 26,346
Shipping and handling costs (1) (2,142) (1,829)
Non-GAAP total operating expenses $ 31,450 $ 24,517
GAAP loss from operations $ (13,966) $ (9,420)
Non-GAAP loss from operations $ (13,966) $ (9,420)
Forward-Looking Statements
Quanterix's current financial results, as discussed in this press release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements about Quanterix's financial performance, including statements under the header "2024 Full Year Business Outlook" set forth above, and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements in this press release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix's actual results to differ from those expressed or implied in the forward-looking statements in this press release include, but are not limited to, those described in our periodic reports filed with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Francis Pruell, Quanterix

Frequently Asked Questions

What were Quanterix's revenues in Q1 2024?

Quanterix reported total revenues of $32.066 million in Q1 2024.

What is the revenue outlook for Quanterix in 2024?

Quanterix projects full-year 2024 revenue between $139 to $144 million.

What significant innovation did Quanterix announce?

Quanterix announced new assays for measuring Tau from brain versus peripheral sources.

What was the net loss for Quanterix in Q1 2024?

Quanterix experienced a net loss of $10.072 million in Q1 2024.

When will Quanterix host its next conference call?

Quanterix's next conference call is scheduled for May 8, 2024, at 8:30 a.m. ET.

Last updated: May 7, 2024